HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Inclusion Criteria: * Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is the predominant cell type. * Locally advanced unresectable or metastatic stage disease * Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for HER2 testing. * At least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing chemotherapy. * Initiation of anticancer therapy for UC after prior progression on platinum-based therapy with or without maintenance avelumab between 01 January 2019 and 12 months before the end of data collection * Radiographically documented and measurable disease progression immediately before index date Exclusion Criteria: * Any concurrent malignant neoplasm requiring systemic therapy during the study window * Enrollment in a therapeutic clinical trial and received non-standard of care treatment during index line of therapy